Logo image of ZURA

ZURA BIO LTD (ZURA) Stock Fundamental Analysis

NASDAQ:ZURA - Nasdaq - KYG9TY5A1016 - Common Stock - Currency: USD

1.68  -0.04 (-2.33%)

After market: 1.64 -0.04 (-2.38%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ZURA. ZURA was compared to 556 industry peers in the Biotechnology industry. While ZURA has a great health rating, there are worries on its profitability. ZURA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZURA had negative earnings in the past year.
In the past year ZURA has reported a negative cash flow from operations.
In multiple years ZURA reported negative net income over the last 5 years.
ZURA had a negative operating cash flow in each of the past 5 years.
ZURA Yearly Net Income VS EBIT VS OCF VS FCFZURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

ZURA has a Return On Assets (-36.08%) which is in line with its industry peers.
With a decent Return On Equity value of -44.96%, ZURA is doing good in the industry, outperforming 67.81% of the companies in the same industry.
Industry RankSector Rank
ROA -36.08%
ROE -44.96%
ROIC N/A
ROA(3y)-30.27%
ROA(5y)N/A
ROE(3y)-48.3%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZURA Yearly ROA, ROE, ROICZURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZURA Yearly Profit, Operating, Gross MarginsZURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

ZURA has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ZURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZURA Yearly Shares OutstandingZURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
ZURA Yearly Total Debt VS Total AssetsZURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ZURA has an Altman-Z score of 0.26. This is a bad value and indicates that ZURA is not financially healthy and even has some risk of bankruptcy.
ZURA has a Altman-Z score of 0.26. This is in the better half of the industry: ZURA outperforms 62.77% of its industry peers.
There is no outstanding debt for ZURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.26
ROIC/WACCN/A
WACCN/A
ZURA Yearly LT Debt VS Equity VS FCFZURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

ZURA has a Current Ratio of 8.19. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.19, ZURA is doing good in the industry, outperforming 71.22% of the companies in the same industry.
ZURA has a Quick Ratio of 8.19. This indicates that ZURA is financially healthy and has no problem in meeting its short term obligations.
ZURA's Quick ratio of 8.19 is fine compared to the rest of the industry. ZURA outperforms 71.40% of its industry peers.
Industry RankSector Rank
Current Ratio 8.19
Quick Ratio 8.19
ZURA Yearly Current Assets VS Current LiabilitesZURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.65% over the past year.
EPS 1Y (TTM)57.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-850%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ZURA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-40.02%
EPS Next 2Y-21.55%
EPS Next 3Y-22.31%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZURA Yearly EPS VS EstimatesZURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZURA. In the last year negative earnings were reported.
Also next year ZURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZURA Price Earnings VS Forward Price EarningsZURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZURA Per share dataZURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A cheap valuation may be justified as ZURA's earnings are expected to decrease with -22.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.55%
EPS Next 3Y-22.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZURA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZURA BIO LTD

NASDAQ:ZURA (7/22/2025, 6:44:45 PM)

After market: 1.64 -0.04 (-2.38%)

1.68

-0.04 (-2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners70.81%
Inst Owner ChangeN/A
Ins Owners7.88%
Ins Owner Change0%
Market Cap103.94M
Analysts84.62
Price Target13.67 (713.69%)
Short Float %2.65%
Short Ratio1.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.67%
Min EPS beat(2)-17.47%
Max EPS beat(2)36.82%
EPS beat(4)1
Avg EPS beat(4)-24.64%
Min EPS beat(4)-106.68%
Max EPS beat(4)36.82%
EPS beat(8)4
Avg EPS beat(8)-47.46%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.21%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS2.23
TBVpS2.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.08%
ROE -44.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.27%
ROA(5y)N/A
ROE(3y)-48.3%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1200%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.19
Quick Ratio 8.19
Altman-Z 0.26
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-850%
EPS Next Y-40.02%
EPS Next 2Y-21.55%
EPS Next 3Y-22.31%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-728.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-725.73%
OCF growth 3YN/A
OCF growth 5YN/A